

PSJ3

Exhibit 134

JAN-MS-00828205

		2005 BP	2005 JU	2005 Actuals as of July	Remaining available to spend in 2005	2005 OE	2006 BP	2005 OE vs 2005 JU Incr/(Decr)	2006 BP vs 2005 JU Incr/(Decr)	2006 BP vs 2005 OE Incr/(Decr)
36067	CP C&E Evra	399,249	382,255	188,983	200,720	389,703	435,400	7,448	53,145	45,697
36068	CP C&E Tri-Cyclen Lo WHC Field	399,249	382,255	198,615	191,088	389,703	435,400	7,448	53,145	45,697
		-	-	-	-	-	27,800	-	27,800	27,800
Total OWH		798,497	764,510	387,598	391,807	779,405	898,600	14,895	134,090	91,395
36073	CP C&E Ditropan XL	260,324	275,647	150,062	190,568	340,630	666,207	64,983	390,560	325,577
36074	CP C&E Elmiron	180,192	243,748	138,637	134,135	272,772	459,781	29,024	216,033	187,009
37527	CP C&E Dapoxetine Urology Field	-	78,750	66,731	15,619	82,350	224,836	3,600	146,086	142,486
		-	-	-	-	-	9,700	-	9,700	9,700
Total OU		440,515	598,146	355,430	340,322	695,752	1,360,525	97,606	762,379	655,073
36069	CP C&E Ultracet	146,165	41,448	115,646	317	115,963	-	74,516	(41,448)	(115,963)
36070	CP C&E Levaquin	1,205,498	1,422,232	480,202	916,504	1,396,706	1,064,175	(25,526)	(358,057)	(332,531)
36178	CP C&E Duragesic CP C&E AP-77	75,677	53,897	87,540	9,453	96,993	-	43,096	(53,897)	(96,993)
		-	-	-	-	-	111,508	-	111,508	111,508
36179	CP C&E Aciphex	1,715,666	1,808,985	1,018,686	980,186	1,998,872	1,636,675	189,887	(172,310)	(362,197)
37528	CP C&E IONSYS	754,968	506,468	97,792	230,354	328,146	414,525	(178,322)	(91,943)	86,379
37575	CP C&E PC Field	85,593	67,993	29,321	64,872	94,193	111,775	26,199	43,782	17,582
Total JOM PC		3,983,567	3,901,023	1,829,187	2,201,686	4,030,873	3,338,658	129,850	(562,366)	(692,216)
36071	CP C&E Topamax Ep	540,433	534,527	253,139	311,085	564,224	627,500	29,697	92,973	63,276
36108	CP C&E Axert	174,326	254,945	193,863	102,351	296,214	294,175	41,269	39,230	(2,039)
36177	CP C&E Razadyne	378,180	270,249	257,032	94,438	351,470	298,025	81,221	27,776	(53,445)
37529	CP C&E Topamax Migr Neurology Field	257,264	302,829	189,782	154,978	344,760	358,200	41,931	55,371	13,440
		-	-	-	-	-	7,800	-	7,800	7,800
Total OMN		1,350,204	1,362,550	893,816	662,852	1,556,668	1,585,700	194,118	223,150	21,232
36175	CP C&E Risperdal	1,329,820	1,429,189	426,965	1,008,718	1,435,683	1,186,925	6,494	(242,265)	(248,759)
36176	CP C&E Risp Consta Psychiatry Field	1,126,065	1,141,350	290,318	895,466	1,185,784	1,042,500	44,434	(98,850)	(143,284)
		-	-	-	-	-	15,000	-	15,000	15,000
Total JPI		2,455,885	2,570,539	717,283	1,904,184	2,621,467	2,244,425	50,928	(326,115)	(377,042)
37525	CP C&E SBG	108,557	157,057	54,036	169,464	223,500	222,500	66,443	65,443	(1,000)
Total CoE		108,557	157,057	54,036	169,464	223,500	222,500	66,443	65,443	(1,000)
Grand Total		9,137,225	9,353,824	4,237,350	5,670,315	9,907,665	9,650,407	553,841	296,583	(257,258)

1 2 3

COMMENTS

1. Increase from JU to OE - \$554K:

Additional costs in changing banners and headers because of company name changes
2005 was the first year housing costs were included in the C&E budgets. No baseline to estimate costs so they may have been underestimated during 2005 Business Planning

2. Increase from JU to 2006 BP - \$455K

Same as above

3. Decrease from OE to 2006 BP - (\$99)K

Several brands dropped out of meetings in 2006
Levaquin reduced by \$333K
Aciphex reduced by \$362K
Risperdal reduced by \$249K
This was leveled out by some brands increasing their meeting participation
Ditropan increased by \$341K
Elmiron increased by \$333K
Dapoxetine increased by \$142K